A Clinical Study to Evaluate the KeraKlear Keratoprosthesis in Patients With Corneal Opacity
NCT ID: NCT03126903
Last Updated: 2019-12-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
11 participants
INTERVENTIONAL
2018-03-22
2019-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Single-Arm
KeraKlear Non-Penetrating Keratoprosthesis
KeraKlear Non-Penetrating Keratoprosthesis
The KeraKlear is a flexible non-penetrating artificial cornea designed to be implanted through small corneal incisions in subjects with corneal opacity.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
KeraKlear Non-Penetrating Keratoprosthesis
The KeraKlear is a flexible non-penetrating artificial cornea designed to be implanted through small corneal incisions in subjects with corneal opacity.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. severe limbal stem cell deficiency (LSCD) associated with aniridia or
2. one full-thickness graft failure and at high risk of a failed second graft; specifically, those who have either young recipient age (age less than 40 years), a history of anterior segment surgery (in addition to prior PKP), and/or pre-operative glaucoma or
3. multiple (two or more) failed cornea transplantation surgeries and spontaneous visual improvement without surgical intervention is not expected or probable.
* Best Corrected Distance Visual Acuity (Snellen) which is equal or worse than 20/200 in the study eye (but at least light perception with projection)
* Estimated visual potential of the study eye is greater than or equal to at least two lines visual improvement of BCDVA of current vision in the study eye.
* Patient and/or caregiver willing and able to insert and remove bandage contact lens.
Exclusion Criteria
* The patient is monocular or the non-study eye has Best Corrected Distance Visual Acuity (Snellen) of worse than 20/160 due to an ocular condition other than severe aniridic limbal stem cell deficiency or failed cornea transplantation surgery(ies).
* Suitable for standard PK with donor tissue in the study eye.
* History of severe dry eye syndrome or a Schirmer test with results of less than 3mm after 5 minutes of testing with the use of topical anesthetic in either eye.
* Active or history of an auto-immune disease (e.g. Rheumatoid Arthritis, Ocular Cicatricial Pemphigoid, Lupus, Steven's Johnson Syndrome, atopic keratoconjunctivitis, etc.).
* On medications that may affect wound healing, such as antimetabolites or other chemotherapeutic agents.
* History of posterior segment eye disease in either eye (including macular degeneration, optic neuropathy, posterior uveitis) which is expected to limit the visual improvement to less than two lines of vision.
* History of retinal surgery in the fellow eye (including retinal detachment repair, intravitreal injection etc.).
* History of retinal surgery in the study eye (including retinal detachment repair, intravitreal injection, etc.) unless the vision is at least light perception with projection in four field quadrants and the macula is attached (if there is no view of the retina, an ultrasound must show the macula is attached).
* History of uncontrolled glaucoma in either eye (IOP has been measured above 25 mmHg at any time in the last 6 months).
* Current use of beta blocker eye drops (e.g. timolol, levobunolol, etc.).
* Vertical cup-to-disc (C:D) ratio greater than or equal to 0.8 in either eye (if able to visible through corneal opacity). If not visible, patient is not to be excluded.
* Limited visual potential (patient does not have the ability to improve a minimum of two lines of vision of BCDVA by history).
* History of amblyopia in the study eye limiting visual potential.
* If the patient has had a corneal transplant, corneal transplantation surgery was performed less than 2 years ago.
* Anticipated need for surgery on the study eye during the course of the study (including cataract surgery).
* Aphakia in the study eye.
* Active ocular infection in either eye.
* Hypotony in the study eye (IOP \< 6mmHg).
* History of herpetic ocular infection in the study eye.
* Corneal thickness less than 400 microns in any region of the pachymetry map, i.e.
lamellar resection depth would be \<100 microns from corneal endothelium accounting for the optic height of the selected implant design (i.e. 300 microns for KeraKlear or 500 microns for KeraKlear XT model).\*.
* Inability to protect the operated eye from trauma.
* Females who are pregnant, lactating, or unwilling to use adequate birth control for t the duration of the study.
* Patient is currently taking Sumatriptan (Imitrex) and unable to discontinue during the study.
22 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Eye Institute (NEI)
NIH
ClinReg Consulting Services, Inc.
OTHER
KeraMed, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of California Irvine
Irvine, California, United States
Cincinnati Eye Institute
Edgewood, Kentucky, United States
Massachussetts Eye and Ear Infirmary
Boston, Massachusetts, United States
Duke University School of Medicine - Dept. of Ophthalmology
Durham, North Carolina, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Kilian R, Lammer J, Roberts P, Rizzo C, Pedrotti E, Marchini G, Schmidinger G. Nonpenetrating Foldable Intrastromal Keratoprosthesis: A Review of the Literature. Cornea. 2024 Jul 1;43(7):909-915. doi: 10.1097/ICO.0000000000003500. Epub 2024 Feb 21.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KERA002
Identifier Type: -
Identifier Source: org_study_id